सैन डिएगो| लैंसेट पत्रिका में प्रकाशित एक अध्ययन में दावा किया गया है कि वयस्कों में क्रॉनिक किडनी रोग (सीकेडी) से पीड़ित कुछ लोगों के इलाज के लिए एक आम मधुमेह की दवा का इस्तेमाल किया जा सकता है। डैपाग्लीफ्लोजिन 'सोडियम ग्लूकोज कोट्रांसपोर्टर-2 (एसजीएलटी2) इनहिबिटर' नामक दवाओं के एक समूह से संबंध रखता है।
एसजीएलटी2 अवरोधक गुर्दे में एसजीएलटी2 प्रोटीन को अवरुद्ध करके काम करता है। इस प्रोटीन को अवरुद्ध करने से गुर्दे में दबाव और सूजन को कम करके गुर्दे की क्षति को कम किया जा सकता है। यह प्रोटीन को मूत्र में रिसने से रोकने में भी मदद करता है, और रक्तचाप और शरीर के वजन को कम करता है।
सीकेडी के साथ 4,304 प्रतिभागियों के नैदानिक परीक्षण से पता चला है कि डैपाग्लिफ्लोजि़न क्रॉनिक किडनी रोग (सीकेडी) के रोगियों में गुर्दे के कार्य में गिरावट की दर को कम करता है।
हालांकि मधुमेह के बिना प्रतिभागियों ने भी डैपाग्लिफ्लोजि़न के साथ गुर्दा समारोह में गिरावट की धीमी दर का अनुभव किया, क्योंकि मधुमेह वाले लोगों में डापाग्लिफ्लोजि़न का प्रभाव अधिक था।
यूनिवर्सिटी मेडिकल सेंटर ग्रोनिंगन के प्रमुख लेखक हिड्डो लैम्बर्स हीर्सपिंक ने कहा, "मुख्य निष्कर्ष यह है कि डैपाग्लिफ्लोजि़न सीकेडी के साथ और बिना टाइप 2 मधुमेह के रोगियों में प्रगतिशील किडनी फंक्शन लॉस को धीमा करने के लिए एक प्रभावी उपचार है।"
हीर्सपिंक ने कहा, "इसलिए, हार्टफेल या मृत्युदर के जोखिम को कम करने के अलावा, डैपाग्लिफ्लोजि़न भी गुर्दे के कार्य में गिरावट की प्रगति को धीमा कर देता है।"
शोध के निष्कर्ष 'एएसएन किडनी वीक 2021' के 4-7 नवंबर अंक में भी प्रस्तुत किए जाएंगे। (एजेंसी)
Thiruvananthapuram, Sep 7 (IANS) All the eight samples of those who were the primary contacts of the 12-year-old boy, who died due to Nipah virus, have turned out negative, said Kerala Health Minister Veena George.The samples of the boy's parents and the health professionals who came in close contact with the boy while being in treatment are all negative. Three samples of each of the eight people were tested at NIV Pune," said George.It was on Sunday the 12-year-old boy died following the Nipah virus attack and it was not until he was taken to three different hospitals in a period of 10 days.Soon after the boy tested positive for Nipah, the health department got into action and identified around 251 people who were in direct or indirect contact. From that list, 54 were short-listed as high risk contacts and of these eight samples, who showed symptoms of fever, were sent for testing at the NIV Pune lab.Others, who had no symptoms, have been asked to go into isolation and they continue to be in isolation in three districts -- Kozhikode, Kannur and Malappuram.A central team of health officials besides a team from NIV Pune are now at Kozhikode and along with the Kerala Health officials are overseeing all the activities and by now 317 health professionals have been given training in handling Nipah, in case an emergency arises.A team of Kerala Veterinary officials are also camping in the district overseeing examination of animals, especially the bats, which are considered to be the source of infection and for that samples have been also collected and send for examination.Meanwhile, the ICMR officials have promised a fresh supply of monoclonal antibodies from Australia, which is expected to reach Kozhikode in the coming days and this is used for treatment.The state health department has set up a separate laboratory for primary testing facility, besides opening a full fledged Nipah ward at the Kozhikode Medical College hospital as a matter of beefing up the treatment facilities.A statewide Nipah management treatment plan has also been formulated and this is being done with the help of the Centre.The last time the state had an attack of Nipah was in 2018, when 17 people lost their lives.--IANSsg/dpb
New Delhi, Sep 6 (IANS) A total of 72 per cent respondents of a survey think that Indian Covid vaccines are safe & effective against the coronavirus. However, 60 per cent of the respondents believe that Indian vaccines are at par with foreign Covid-19 vaccines.The survey 'Public Ki Awaaz Poll' was conducted by location-based social networking app "Public" to examine the extent of vaccine hesitancy. The poll garnered a total of 9,14,164 responses to find out the vaccine hesitancy. According to the survey, 8.8 per cent of the respondents expressed hesitation in getting vaccinated against the virus. According to the aggregate estimates, a large chunk of respondents considers it safe to take the vaccine. Around 72 per cent strongly agree that the vaccines are safe & effective and over a majority of 60 per cent respondents believe that Indian vaccines are at par with foreign Covid-19 vaccines. Around 25 per cent of the respondents said that they've already been vaccinated with both the doses.Although the majority of respondents favoured vaccines, the survey showed that 18 per cent of the respondents still haven't received even a single dose while 8.8 per cent were not sure of getting vaccines. A meagre 4 per cent strongly expressed their mistrust against the vaccines.The potential risk of side effects was the most cited reason of about 34 per cent for not administering the vaccines. As per the findings, other factors that lead to vaccine hesitancy are lack of trust for 20 per cent, health concerns for 14 per cent and never having taken any vaccine for 11 per cent.According to the poll, both community and institutional encouragement are essential in this regard. 24 per cent of the respondents said that their confidence in the efficacy of vaccines is based on the recommendations of friends and family, while 25 per cent said that they'll go by the word of healthcare experts.The vitality of information is indicated in the responses of the participants as 23 per cent hold the view that access to more information on the vaccines can help shore up confidence.On the question of 'getting information and updates on the vaccines', a whopping majority of 59 per cent respondents marked media as an important source, whereas 15 per cent rely on government ads. Around 13 per cent of the respondents said that they depend on friends and family, while 11 per cent cited other sources as means of obtaining information.--IANSavr/rs
An Ayurvedic poly-herbal formulation, NEERI-KFT, has the potential to not only slow down the progression of chronic kidney disease but also restore normalcy in functional parameters of the vital organ, a team of researchers has claimed.
In a review published in the latest edition of Saudi Journal of Biological Sciences, they said "phytopharmacological evaluation of NEERI-KFT suggests that it exhibits substantial potential against oxidative and inflammatory stress induced apoptosis by exerting antioxidant, nephroprotective and immunomodulatory effects...in the patients associated with renal dysfunction or chronic kidney disease (CKD)".
The NEERI-KFT, a herbal medicine extracted from plants, has been found to correct oxidative as well as inflammatory stress known for reducing body's immunity, said the authors after drawing data on the formulation for kidney ailments from more than five electronic databases such as Science Direct, Google Scholar, Elsevier, PubMed, Springer, ACS publication from published database between 2000 and 2020.
Buy Online► Aimil Neeri KFT Syrup
The study, 'A systematic review on nephroprotective AYUSH drugs as constituents of NEERI-KFT' not only examined the impact of the herbal extract of NEERI-KFT prepared by the AIMIL Pharma interventions on patients, but also dwelled in detail the adverse events of the modern medicine used for the management of the kidney ailments.
The study also highlighted the herbal drug's efficacy in reducing "serum creatinine, blood urea, and serum uric acid as compared to placebo group" and described "its well-tolerated effect with no adverse hematological or biochemical abnormalities occurred to any subjects during clinical trial".
"It can be suggested that NEERI-KFT can be an alternative and complementary therapy at end-stage renal disease (ESRD) or complete loss of kidney function where frequent dialysis of renal transplant remains only a single option for continued survival CKD patients," researchers said.
K.K. Sharma, AIMIL Pharma Managing Director, attributed this to the "more than 20 different potent herbs like haridra, varuna, shirish, gokhru, punarnava and anantamul to name a few in the formulation which are known for their nephro corrective, anti-inflammatory and antioxidant properties and reparative regeneration of kidney cells.
Also, Read This► किडनी के लिए संजीवनी बनी आयुर्वेदिक दवा नीरी केएफटी : अध्ययन
It was after a string of stringent tests that this formulation has been developed to provide relief to kidney patients, he said.
K.N. Dwivedi from Banaras Hindu University said the herbal ingredients in NEERI-KFT are loaded with many anti-oxidants besides medicinal values which not only strengthen kidney but liver also.
"This is a very unique drug and we have found it very effective in our study also," he added.
Read More► Aimil Neeri KFT Syrup: Benefits, Side Effects, Composition and Dosage
Chandigarh, Aug 20 (IANS) Haryana Chief Minister Manohar Lal Khattar on Friday said the state has been giving a benefit of Rs 2 lakh to poor families under an insurance scheme, who have lost members during the Covid-19 pandemic.The Chief Minister informed the state assembly about this during the Question Hour on the first day of the monsoon session that commenced here.Adequate arrangements have been made for ensuring uninterrupted oxygen supply during the pandemic, he said."Initially, Haryana got a quota of 150 metric tonnes (MT) oxygen from the Centre, which was later increased to 285 MT, although the state had demanded 350 MT," he said.The Chief Minister said to ensure uninterrupted oxygen supply, adequate arrangements were made. No discrimination of any kind was done in the supply of oxygen. During the second wave, the daily oxygen supply and requirement were calculated thoroughly, he said."Not only this, concentrators were also brought to ensure adequate supply of oxygen. Many social organizations also contributed to this," said Khattar."Currently, there are 670 active COVID-19 cases in Haryana. A third wave is expected. Even today many people are struggling with post-Covid complications. Pandemic is not in anyone's control. We have done our duty in times of crisis," added Khattar.He blamed the opposition for criticizing the government on every issue.Replying to another question, Cooperation Minister Banwari Lal, on behalf of Health Minister Anil Vij, said 26 healthcare personnel, comprising nine doctors and eight paramedical staff, lost their lives while performing Covid-19 duty. They were covered under a life insurance scheme.He said the state saw 9,635 Covid deaths and district-level death audit committees were constituted to evaluate the cause of death so that corrective measures were taken accordingly.--IANSvg/bg
Toronto, Aug 12 (IANS) Scientists at the University Health Network (UHN) here have conducted a first-in-the-world randomised placebo-controlled trial of third dose Covid-19 booster vaccine for transplant patients that shows substantially improved protection.Persons who have received an organ transplant are considered to be at increased risk for Covid-19 and for a severe outcome because their immune systems are necessarily suppressed to ensure their transplants are successful and lasting.The study, published in the New England Journal of Medicine, has shown that a third dose of Covid vaccine is the best way to increase protection in them.The team enrolled 120 transplant patients between May 25 and June 3. None of them had Covid previously and all of them had received two doses of the Moderna vaccine. Half of the participants received a third shot of the vaccine (at the 2-month mark after their second dose) and the other half received placebos.The primary outcome was based on antibody level greater than 100 U/ml against the spike protein of the virus. In the placebo group -- after three doses (where the third dose was placebo), the response rate was only 18 per cent whereas in the Moderna three-dose group, the response rate was 55 per cent."This is an important win for our patients because the results are quite conclusive," said Dr Atul Humar, Medical Director of the Ajmera Transplant Centre, UHN."The third dose was safe and well tolerated and should lead to a change in practice of giving third doses to this vulnerable population," he added.In addition, 60 per cent of the patients in the Moderna group also developed neutralising antibodies versus 25 per cent in the placebo group.There was also a substantial improvement in the ability of the three-dose Moderna group to allow the patients to develop a robust T-cell response against the virus.Moreover, the third booster vaccine was found to be very well tolerated with only mild side effects and did not cause acute organ rejections -- an important finding, as there were concerns that repeated vaccinations could increase the incidence of organ rejection in transplant recipients, the researchers said.--IANSrvt/vd